Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of LY3454738 in Healthy Participants
NCT06173895Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ucenprubart in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration at 85 days and Area Under the Concentration Versus Time Curve at 85 days. Started Jan 2024; status: completed.
02
Drugs
ucenprubart
03
Conditions
atopic dermatitis (AD)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06173895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173895.